01. Letter from the President

Dear Friends,

There has been a lot of activity at the ECFS since the last edition of our newsletter and here is a brief review of the special projects, what's new with our society and a few highlights of the upcoming 40th European Cystic Fibrosis Conference taking place in a few days, this year in Seville, Spain.

But first, let me remind you of the ECFS elections, which are taking place this month. Definitely time flies as we use to say! I personally will finish my term as president in 2018 and the new president will be elected this year in order to have a smooth transition. Isabelle Fajac applied for President of the ECFS.

We also have two positions as Board members. The candidates for these positions are: Jeffrey Beekman, Marcus Mall and Kevin Southern.

If you have not voted so far, you will still have the possibility to do so until Thursday 08 June, 19:00. The results of the elections will be announced at the AGM on Friday 09 June (18:30-19:30). We very much hope that as many of you as possible will attend the AGM. We value your involvement and it is really important to have members contribute and input new ideas. More information on the AGM will appear further down in the newsletter.

In January, the ECFS Clinical Trials Network and the ECFS Patient Registry held their Steering Group meetings in Lisbon, Portugal. Both the CTN and ECFSPR remain key projects of the Society. The support of
several national organisations continues to be greatly appreciated and we look forward to working closely
with them and increasing our partnerships in the future.

The **14th ECFS Diagnostic Network Working Group** Meeting took place in Ljubljana, Slovenia, 16-17
February 2017, hosted by Ana Kotnik Pirs.

The **ECFS Basic Science Conference** was held in Albufeira, Portugal, 29 March-01 April. With a record
number of abstracts and of attendees, the conference was a resounding success. We would like to thank
the organizers, Ineke Braakman (NL), Marcus Mall and Tzyh-Chang Hwang (US) for putting together a high-
quality programme. The [abstract book](#) is available on the ECFS website.

We are rapidly approaching our summer conference in Seville and the final preparations are well under
way. The Scientific Committee has put together an outstanding programme and we have some exciting
new basic research and results from clinical trials to discuss. You can find the [final programme](#) on the
ECFS website. We would like to thank the Scientific Committee and the Steering Committee for all their
hard work over the last year in preparing the programme, selecting the abstracts and sorting the various
sessions. Besides the conference Smartphone Application featuring the programme and other useful
information, other recent initiatives include the Interactive Poster Discussion session, some morning
‘meet the expert’ sessions and the ECFS Tomorrow lounge which will feature a series of interesting
sessions. This year, we will organise two CF courses: one in English and one in Spanish. Beside the
course, we will also offer simultaneous translation to Spanish for several symposia.

As part of our commitment to support young researchers, three Young Investigators Awards and 20
courses have been awarded to young investigators based on the merit of their abstract
submissions.

Please don’t miss a visit to the “CF Community” booth area in the Exhibition Hall for information on the
various initiatives and programmes. If you are looking for a position or have a job opening to advertise,
please send us the information to post on the website and bring an A4 advertisement to the ECFS booth
at the conference.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in Cystic Fibrosis
contained at the end of this Newsletter.

Please contact us if you have news items you would like to have included in future Newsletters or
published on our website.

Yours sincerely,

Kris De Boeck
ECFS President
02. ECFS Board Elections – Cast your vote!

The ECFS is holding elections for the ECFS President elect and 2 ECFS Board Members Positions. Invitations to take part in the elections have been sent to the ECFS electorate by email and access to the online secured voting poll can be found on the ECFS website page below once logged in.

Candidates’ information and links to supporting documents such as the candidates’ nominations, application letters and CVs are available on the ECFS website at [https://www.ecfs.eu/ecfs-board-elections-2017](https://www.ecfs.eu/ecfs-board-elections-2017)

Job Descriptions are available for both the President and Board members. [President’s Job Description](https://www.ecfs.eu/ecfs-board-elections-2017) | [Board Member’s Job Description](https://www.ecfs.eu/ecfs-board-elections-2017)

**POLLS CLOSE THURSDAY 8 JUNE 2017, 19:00 CEST**

03. ECFS Annual General Meeting @ Seville 2017

The Annual General Meeting will be held on Friday, 09 June 2017, 18:30-19:30, at the Conference Centre in Seville (Auditorium 2).

The Annual General Meeting agenda:
1. President’s Report – Kris De Boeck
2. Secretary’s Report – Harm Tiddens
3. Treasurer’s Report –
4. ECFS Board elections – Harm Tiddens
5. Update on Journal of Cystic Fibrosis – Scott Bell
6. CTN Report – Tim Lee
7. ECFS Patient Registry Report – Lutz Naehrlich
8. ECFS Standards of Care Report – Pavel Drevinek
9. ECFS Working Group Reports
   - Diagnostic Network Working Group – Nico Derichs
     – Margarida Amaral and Marcus Mall
10. ECFS Special Interest Group Reports
    - [ECFS Nurse Special Interest Group](https://www.ecfs.eu/ecfs-board-elections-2017) – Ellen Julie Hunstad
    - ECFS Cystic Fibrosis Pharmacy Group – Keith Thompson
11. Presentation of the 2018 European CF Conference
12. Any Other Business

We hope to see you!
04. Seville Conference

Seville will welcome the annual ECFS conference this year. You can find all the details about the scientific programme [here](#).

- Below are some highlights of the conference. **Looking forward to seeing you in Spain!**

The **Interactive Poster Discussion** session aims at fostering discussion on a chosen theme.

*Join us on Friday, 9 June – 17:00-18:30*

**IPD 1**: Discussion on the themes of non-tuberculous mycobacteria and fungal infections.

**IPD 2**: Discussion on Adherence
05. Seville 2017 Smartphone Application

The number of delegates using the Conference Smartphone App increases each year. Through the app, you will be able to view all the information on the scientific programme, the exhibitors, the abstracts and ePosters. The ECFS 2017 Conference App is designed to enhance the experience of the participants before, during and after the Conference. New features this year include the possibility of networking with other delegates via the My Community button, the access to the voting system available in some designated interactive session. This year you will have the possibility to take selfies that will be shown on our selfie wall in the CF Community area. So why don’t you show us your talent as a photographer? Further information is available on the conference website and the App will be ready to download in the coming days.

06. ECFS Award 2017

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of Cystic Fibrosis or to the treatment or care of patients with Cystic Fibrosis. This year, the ECFS wishes to acknowledge Dr. Jeffrey Beekman for his substantial and remarkable contribution to cystic fibrosis over the past years. Dr. Beekman was appointed as head of the CF lab of the pediatric pulmonology department in Utrecht in 2008. Coming from a Basic Science environment outside CF, he was very eager to learn the clinical aspects of the disease right from the beginning. He
developed as a pioneer in translational medicine with a great drive to bring laboratory discoveries into clinical care.

Dr. Beekman was at the basis of the CF intestinal organoid model. The Hubrecht lab had discovered the intestinal stem cell and elaborated stem cell cultures into so-called miniguts (organoids). Dr. Beekman and his team initiated a breakthrough in the field by developing a functional CFTR assay in this model. This resulted in both a method enabling personalised medicine in individual patients and a screening platform for new compounds.

The model already changed the lives of CF-patients. Several patients with unique genotypes shown to be responsive to correctors/ potentiators ex vivo were successfully treated afterwards. Several insurance companies in the Netherlands accepted the combined ex vivo/in vivo responsiveness in individual patients as basis for reimbursements.

Besides several top-publications in Nature, Cell Stem Cell and Science Translational Medicine, the CF-organoid model attracted broad international media attention, raising further public awareness for CF. Dr. Beekman has shown to be a great communicator towards scientists, clinicians and patients. He frequently contributes to the ECFS, BSM and NACF conferences.

**07. Gerd Döring Award**

Professor Gerd Döring was an outstanding leader of the ECFS. The support of young investigators was a high priority for him and to honour his enormous contribution, the ECFS has initiated a Gerd Döring Award that is given annually to honour an exceptional early career young European scientist. This year, the Gerd Döring Award has been granted to Viola Camilla Scoffone, in acknowledgement of her recent remarkable contribution to Cystic Fibrosis. The Award, which includes a monetary grant of 5.000 Euro to support research, will be presented during the Opening Plenary of the Seville Conference.

Viola has the opportunity to present her work on *B. cepacia* at the Seville conference in the Late Breaking Science Session scheduled on Friday 09 June at 17:00

**08. Meet the experts sessions**

In these small interactive breakfast sessions you will have the opportunity to ask questions and discuss a specific topic with experts from the field. The format encourages lively discussions and a more personal approach to learning. Please note that you must register to attend Meet the Experts sessions. To sign up, please contact the registration desk onsite.

**Thursday 8 June, 07:15-08:15**

| Meet the Experts – Transplantation |
| Experts: Dirk Van Raemdonck, Leuven, BE / Amparo Solé, Valencia, ES | ePoster Corner B |
| Meet the Experts – Next generation microbiology and diagnostics |
| Experts: Eshwar Mahenthiralingam, Cardiff, UK / Jean-Marc Rolain, Marseille, FR | ePoster Corner C |
| Meet the Experts – How to publish? |
| Experts: Scott Bell, Brisbane, AU / Stuart Elborn, London, UK | Tomorrow Lounge |

**Friday 9 June, 07:15-08:15**

| Meet the Experts – Exercise and bone |
| Experts: Esther Quintana Gallego, Seville, ES / Helge Hebestreit, Würzburg, DE | ePoster Corner B |
| Meet the Experts – Psychopharmacological treatments for mental health problems in cystic fibrosis |
| Experts: Anna Georgiopoulou, Boston, US / Angelika Graf, Berlin, DE | ePoster Corner C |
| Meet the Experts – Writing successful grant applications and scientific papers |
| Expert: Luis Galietta, Pozzuoli, IT | ECFS Tomorrow Lounge |
We see the ECFS Tomorrow as a means to improve one of the fundamental objectives of the Society – to support and engage young scientists working in the field of Cystic Fibrosis. It is essential to provide professionals who are new to the community with opportunities to connect in a meaningful way with current leaders and experts. In turn, the new generation of specialists bring up-to-date approaches and practices to the wealth of experience that already exists within the society’s ranks.

Located adjacent to the Exhibition Area, the ECFS Tomorrow Lounge will feature interactive workshops and a debate on Thursday and Friday. Come and take an active part in the debate and discussions on different aspects of cystic fibrosis management and care.

**WEDNESDAY, JUNE 7**

- **20:00 – 21:00** Meet & Greet

**THURSDAY, JUNE 8**

- **07:15 – 08:15** Meet the experts - How to publish?
  Scott Bell, Brisbane, AU / Stuart Elborn, London, UK

- **12:45 – 13:45** Mental health guidelines: how to get started?
  Practical strategies and challenges
  ECFS Mental Health Working Group

- **14:00 – 15:00** Creative methods of intervention*
  Diana Kadosh, Petah Tikva, IL

**FRIDAY, JUNE 9**

- **07:15 – 08:15** Meet the experts - Writing successful grant applications and scientific papers
  Luis Gaietta, Pozzuoli, IT

- **12:45 – 13:45** Drug administration (nebulisers, new therapies)
  Ann Ramon, Ghent, BE / Nicola Shaw, Leeds, UK

- **14:00 – 15:00** PRO/CON Debate – the Specialist CF Pharmacist is an essential member of the clinical team in the care of people with CF
  Nicola Shaw, Leeds, UK

- **15:15 – 16:15** CFRD - Future nutritional considerations
  Sarah Collins, London, UK

**SATURDAY, JUNE 10**

- **10:30 – 11:00** Farewell coffee

### 10. Meetings at the Seville Conference

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tuesday 6 June 2017</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>ECFS Board Meeting*</td>
<td>Madrid 2</td>
</tr>
<tr>
<td>08:30</td>
<td>Physiotherapy Short Course - Exercise in CF: from evaluation to prescription**</td>
<td>Bruselas 3</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>15:00</td>
<td>ACTIVATE-CF Meeting*</td>
<td>Paris 2</td>
</tr>
<tr>
<td>09:00</td>
<td>CF Course - A tour of CF- The essential tool kit **</td>
<td>Paris 3</td>
</tr>
<tr>
<td>09:00</td>
<td>CF Course - un Recorrido por la Fibrosis quística – ‘Herramientas Esenciales’**</td>
<td>Paris 4</td>
</tr>
<tr>
<td>17:00</td>
<td>CFTR3 Investigator Meeting *</td>
<td>Paris 2</td>
</tr>
<tr>
<td>13:15</td>
<td>ECFS CTN Steering Group Meeting*</td>
<td>Roma</td>
</tr>
<tr>
<td>08:30</td>
<td>ECFS CTN Training and Development*</td>
<td>Roma</td>
</tr>
<tr>
<td>09:00</td>
<td>ECFS Exercise Working Group*</td>
<td>Paris 2</td>
</tr>
<tr>
<td>09:30</td>
<td>ECFS Neonatal Screening Working Group</td>
<td>Auditorium2</td>
</tr>
<tr>
<td>08:30</td>
<td>ECFS Nursing Special interest Group Meeting**</td>
<td>Auditorium3</td>
</tr>
<tr>
<td>13:30</td>
<td>ECFS Patient Registry Executive Committee Meeting*</td>
<td>Bruselas 2</td>
</tr>
<tr>
<td>16:30</td>
<td>ECFS Patient Registry Harmonisation Group meeting*</td>
<td>Bruselas 2</td>
</tr>
<tr>
<td>12:15</td>
<td>ECFSPR – CFE Joint Project Meeting*</td>
<td>Madrid 2</td>
</tr>
<tr>
<td>14:00</td>
<td>European CF Pharmacy Group Meeting</td>
<td>Madrid 2</td>
</tr>
<tr>
<td>09:00</td>
<td>European Cystic Fibrosis Nutrition Group</td>
<td>Madrid 1</td>
</tr>
<tr>
<td>09:30</td>
<td>European Psychosocial Special Interest Group (EPSIG) Meeting**</td>
<td>Bruselas 1</td>
</tr>
<tr>
<td>12:30</td>
<td>International Physiotherapy Group for Cystic Fibrosis Annual General Meeting</td>
<td>Bruselas 3</td>
</tr>
<tr>
<td>08:15</td>
<td>Physiotherapy Short Course - Exercise in CF: from evaluation to prescription**</td>
<td>Bruselas 3</td>
</tr>
<tr>
<td>14:30</td>
<td>Physiotherapy Case Presentations**</td>
<td>Bruselas 3</td>
</tr>
<tr>
<td>08:00</td>
<td>CFHealthHub - National Self Management Collaborators Meeting*</td>
<td>Roma</td>
</tr>
<tr>
<td>18:30</td>
<td>ECFS CTN Patient Reported Outcome Measures Group Meeting</td>
<td>Bruselas</td>
</tr>
<tr>
<td>12:30</td>
<td>ECFS CTN Standardisation Committee Meeting*</td>
<td>Paris</td>
</tr>
<tr>
<td>13:30</td>
<td>ECFS Patient Registry - Meeting for Interested Parties</td>
<td>Bruselas</td>
</tr>
<tr>
<td>12:30</td>
<td>ECFS Patient Registry Data Quality Project Group Meeting*</td>
<td>Roma</td>
</tr>
<tr>
<td>18:00</td>
<td>ECFS Patient Registry Software training</td>
<td>Roma</td>
</tr>
<tr>
<td>10:00</td>
<td>ECFSPR Scientific Committee Meeting*</td>
<td>Roma</td>
</tr>
<tr>
<td>12:30</td>
<td>ECFS Standards of Care Group Meeting</td>
<td>Auditorium2</td>
</tr>
<tr>
<td>19:00</td>
<td>European CF Registry Forum*</td>
<td>Auditorium2</td>
</tr>
<tr>
<td>14:00</td>
<td>Cystic Fibrosis Trust Fringe Meeting*</td>
<td>Roma</td>
</tr>
<tr>
<td>18:30</td>
<td>ECFS Annual General Meeting*</td>
<td>Auditorium2</td>
</tr>
<tr>
<td>12:30</td>
<td>ECFS Diagnostic Network Working Group Meeting</td>
<td>Bruselas</td>
</tr>
<tr>
<td>12:30</td>
<td>ECFS Mental Health Working Group Meeting</td>
<td>Auditorium2</td>
</tr>
<tr>
<td>15:00</td>
<td>ECFS Patient Registry Software training – walk in session</td>
<td>Roma</td>
</tr>
<tr>
<td>12:30</td>
<td>ECFS Patient Registry Steering Group Meeting*</td>
<td>Paris</td>
</tr>
<tr>
<td>07:00</td>
<td>Journal of Cystic Fibrosis Editorial Board Meeting*</td>
<td>Roma</td>
</tr>
<tr>
<td>13:30</td>
<td>ECFS Scientific Committee Meeting - Belgrade 2018*</td>
<td>Roma</td>
</tr>
</tbody>
</table>

* By invitation only
** Extra registration needed
11. 2017 ECFS Basic Science Conference – Albufeira, Portugal

The ECFS Basic Science Conference was held in Albufeira, Portugal between 29 March and 01 April 2017. With another record number of abstracts and of attendees (nearly 250), the conference was a resounding success. We would like to thank the organisers, Ineke Braakman (NL), Marcus Mall (DE) and Tzyh-Chang Hwang (US) for putting together a high quality programme. The abstract book is available on the ECFS website.

Marcus Mall (DE), Isabelle Callebaut (FR) and John Engelhardt (US) already accepted to chair the 2018 edition of the Basic Science Conference. It will be organised in Greece, 21-24 March 2018

12. ECFS Short Term Clinical Fellowship

Here is the letter sent by a recipient of the CF Preceptorship Programme

As a young Cystic Fibrosis (CF) pulmonologist at the early stages of taking care of adult CF patients at the Cystic Fibrosis Centre of the Bern University Hospital, I was pleased to have had the opportunity to receive an ECFS preceptorship which included a participation in a comprehensive, multidisciplinary pediatric and adult CF course followed by a two-week observership at the pediatric and adult CF centre at Royal Brompton Hospital London.

I didn’t really know what to expect from the CF course prior to start. The schedule which we received at the beginning revealed to be a multifaceted program with various presenters, mainly from the UK and from different disciplines as well as institutions. Although it was relatively compact, it left enough time for questions at the end of most of the presentations. We also formed smaller working groups for a case presentation at the end of the course. Especially emotional was the talk about their life experience of a mother of two young CF patients and an adult CF patient who received a lung transplant. It was impressive how well the mother dealt with her first child’s fate who, unfortunately, did not survive until a lung transplant. The course was ended with a nice interactive quiz and a little prize for the winner team where each member of the small working group actively participated.

The observership gave a good insight into the pediatric and adult CF care at a large CF centre. Since I mainly work with adults CF patients, I predominantly spent time with the adult team. Due to the clinical experience from years of CF care treatments sometimes differed slightly from current CF guidelines if alternative options were already tried in the past.

I enjoyed the multidisciplinary approach of the weekly ward rounds prior to bedside rounds in the adult CF care as well as the multidisciplinary exchange of thoughts each afternoon prior to the adult CF clinic.
three times weekly. I felt the team spirit with mutual respect among consultant nurses, clinical nurse specialists, house officers, registrars, consultants and head of the adult CF centre. Altogether the experience during the three weeks in London enriched me not only in a medical but also in an interpersonal way. Big “Thank you” to Christine Dubois from the ECFS!

Dagmar Lin

13. Announcements
Michele Milo, a student from the Bari (Italy) CF centre is looking for a co-supervisor for a project on ‘cardiovascular diseases in patients with CF’. He has studied atherosclerosis risk factors, media remodelling and vascular disease CFTR associated and has done an initial data analysis. The task of the co-supervisor will be to provide input on the analysis and the presentation of the report.

The student’s contact details are: m.milo@studenti.uniba.it

14. Upcoming Events
- ECFS Board Meeting 06 June 2017, Seville, Spain
- ECFS Annual General Assembly - 09 June 2017 – Seville, Spain
- 40th European CF Conference - 07-10 June 2017 – Seville, Spain
- Hands-on Workshop Epithelial Systems: Physiology & Pathophysiology, Lisbon, PT, 24-28 July 2017
- 2017 European Respiratory Society Congress 09-13 September 2017 – Milan, Italy
- North American CF Conference, 02-04 November 2017, Indianapolis, IN, United States
- 41st European CF Conference – 6-9 June 2018, Belgrade, Serbia

15. Current References in Cystic Fibrosis
Please go to next page.
**CF Reference List**

**Adults & Adolescents**

Askew K., Bamford J., Hudson N., Moratelli J., Miller R., Anderson A., Doe S., Bourke SJ.
Current characteristics, challenges and coping strategies of young people with cystic fibrosis as they transition to adulthood
Clinical Medicine 2017; 17: 121 - 125

Adherence to infection prevention and control guidelines: A vignette-based study of decision-making and risk-taking in young adults with cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 146 - 150

Bregnall V., Boisen KA., Schiotz PO., Pressler T., Lomborg K.
Flying the nest: a challenge for young adults with cystic fibrosis and their parents
Patient Preference and Adherence 2017; 11: 229 - 236

Chambers R., Lucht A., Reihill A., Hough J.
Prevalence and impact of pelvic floor dysfunction in an adult cystic fibrosis population: a questionnaire survey

Chen E., Killeen KM., Peterson SJ., Saulitis AK., Balk RA.
Evaluation of Pain, Dyspnea, and Goals of Care Among Adults With Cystic Fibrosis: A Comprehensive Palliative Care Survey
American Journal of Hospice & Palliative Medicine 2017; 34: 347 - 352

Choyce J., Shaw KI., Sitch AJ., Mistry H., Whitehouse JI., Nash EF.
A prospective pilot study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised controlled trial
BMC Pulmonary Medicine 2017; 17:

Frankenfield DC., Ashcraft CM., Drasher TL., Reid EK., Vender RL.
Characteristics of Resting Metabolic Rate in Critically Ill, Mechanically Ventilated Adults with Cystic Fibrosis
Journal of Parenteral and Enteral Nutrition 2017; 41: 601 - 606

Kazmerski TM., Gmelin T., Slocum B., Borrero S., Miller E.
Attitudes and Decision Making Related to Pregnancy among Young Women with Cystic Fibrosis

Ladones S., Kazmerski TM., Rowe SM.
A Case Report of Pregnancy during Use of Targeted Therapeutics for Cystic Fibrosis

Michi RK., Mues S., Mainz JG., Markert UR.
Hereditary Metabolic Diseases Pregnancy during Mucoviscidosis - an Overview
Geburtshilfe und Frauenheilkunde 2017; 77: 19 - 25

Adolescents with cystic fibrosis: the approach to transition from paediatric to adult care
Archives de Pediatrie 2016; 23:

Reisinho MDMSRO., Gomes BP.
Nursing interventions in monitoring the adolescent with Cystic Fibrosis: a literature review
Revista Latino-Americana de Enfermagem 2016; 24: ArNo: e2845

Waters KA., Lowe A., Cooper P., Vella S., Selvadurai H.
A cross-sectional analysis of daytime versus nocturnal polysomnographic respiratory parameters in cystic fibrosis during early adolescence
Journal of Cystic Fibrosis 2017; 16: 250 - 257

**Animal Model**

Growth deficits in cystic fibrosis mice begin in utero prior to IGF-1 reduction

Partial Restoration of CFTR Function in CFTR-Null Mice following Targeted Cell Replacement Therapy
Molecular Therapy 2017; 25: 654 - 665

Gauthier TW., Grunwell JR., Pang XD., Harris FL., Brown LAS.
Impaired defenses of neonatal mouse alveolar macrophage with CFTR deletion are modulated by glutathione and TGF beta 1
Physiological Reports 2017; 5: 6:e10896

Aerosolised bovine lactoferrin reduces neutrophils and pro-inflammatory cytokines in mouse models of Pseudomonas aeruginosa lung infections
Biochemistry and Cell Biology 2017; 95: 41 - 47

**Antimicrobials**

Ahn Y., Kim JM., Kweon O., Kim SJ., Jones RC., Woodling K., da Costa GG., LiPuma JJ., Hussong D., Marasa BS., Cerniglia CE.
Intrinsic Resistance of Burkholderia cepacia Complex to Benzalkonium Chloride
mBio 2016; 7: 6:e01716

Amin R., Waters V.
Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 7:CD009249

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revivedantibiotic
Scientific Reports 2017; 7: ArNo: 40208

Chung PY.
Plant-derived Compounds as Potential Source of Novel Anti-Biofilm Agents Against Pseudomonas aeruginosa
Current Drug Targets 2017; 18: 414 - 420

Ciofu O., Rojo-Molinero E., Macia MD., Oliver A.
Antibiotic treatment of biofilm infections
APMIS 2017; 125: 304 - 319

Crararo EF., Porsio B., Schillaci D., Cusiman MGM., Spigolon D., Giamonna G., Cavallaro G.
Polyamin-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
Nanomedicine 2017; 12: 25 - 42

Crass RI., Rutter WC., Burgess DR., Martin CA., Burgess DS.
Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin
Antimicrobial Agents and Chemotherapy 2017; 61: 4:e02239

Dassner AM., Sutherland C., Giroto J., Nicolau DP.
In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside
In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside
Infectious Diseases and Therapy 2017; 6: 129 - 136
El-Seedy A., Pasquet MC., Shafiek H., Morsi T., Kitizs A., Ladeveze V.
Cystic Fibrosis Membrane Conductance Regulator (CFTR) gene mutations in North Egyptian population: implications for the genetic diagnosis in Egypt
Cellular and Molecular Biology 2016; 62: 21 - 28

Embark HM.
Regulation of CFTR chloride channel trafficking by Nedd4-2: role of SK1
Physiology and Pharmacology 2017; 21: 54 - 62

Farinha CM., Canato S.
From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking
Cellular and Molecular Life Sciences 2017; 74: 39 - 55

The Cystic Fibrosis Transmembrane Conductance Regulator Controls Biliary Epithelial Inflammation and Permeability by Regulating Src Tyrosine Kinase Activity
Hepatology 2016; 64: 2118 - 2134

Fossett JK.
CFTR nonsense mutations: Therapeutic benefits from clinically approved drugs?
Journal of Cystic Fibrosis 2017; 16: 9 - 10

Gelfond D., Heitshs S., Ma CX., Rowe SM., Frederick C., Uluer A., Siciliana L., Konstan M., Tullis E., Roach RNC., Griffin K., Joseff E., Borowitz D.
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients with Cystic Fibrosis and the G551D Mutation
Clinical and Translational Gastroenterology 2017; 8: ArNo: e81

Correctors and Potentiators Rescue Function of the Truncated L551F CFTR Mutant
Journal of Biological Chemistry 2017; 292: 3706 - 3719

Hildebrandt E., Khazanov N., Kappes J., Dai Q., Sendorowit H., Urbatsch IL.
Specific stabilization of CFTR by phosphatidylinerine Biochimica et Biophysica Acta-Subcellular Biology 2017; 1859: 289 - 293

Knauf F., Thomason RB., Heneghan JF., Jiang ZK., Adehamio A., Thomason CL., Barone C., Asplin JR., Egan ME., Alper SL., Arsonson P.
Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion
Journal of the American Society of Nephrology 2017; 28: 242 - 249

Langron E., Simone ML., Delalande CMS., Reymond JL., Selwood DL., Vergani P.
Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds
British Journal of Pharmacology 2017; 174: 525 - 539

Lee S., Phuan PW., Felix CM., Tan JA., Levin MH., Verkman AS.
Nonmonal-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prospective Therapy of Dry Eye Diseases
Journal of Medicinal Chemistry 2017; 60: 1210 - 1218

Li M., Soroka CJ., Harry K., Boyer JL.
role of G1K
CFTR-associated ligand is a negative regulator of Mrp2 expression
American Journal of Physiology-cell Physiology 2017; 312: C40 - C46

Linsdell P.
Architecture and functional properties of the CFTR channel pore
Cellular and Molecular Life Sciences 2017; 74: 67 - 83

Liu FY., Zhang Z., Canady L., Gadsby DC., Chen J.
Molecular Structure of the Human CFTR Ion Channel
Cell 2017; 169:

MassIP-Coopiz MM., Clauzure M., Valdivieso AG., Santa-Coloma TA.
CFTR impairment upregulates c-Src activity through IL-1 beta autocrine signaling
Archives of Biochemistry and Biophysics 2017; 616: 1 - 12

Meng X., Clews J., Kargas V., Wang XM., Ford RC.
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
Cellular and Molecular Life Sciences 2017; 74: 23 - 38

Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation
Journal of Biological Chemistry 2017; 292: 3706 - 3719

Molina LCP., Pinto NA., Rodriguez PT., Romarowski A., Sanchez AV., Viscioni PE., Darson A., Trevino CL., Buffone MG.
Essential Role of CFTR in PKA-Dependent Phosphorylation, Alkalization, and Hyperpolarization during Human Sperm Capacitization
Journal of Cellular Physiology 2017; 232: 1404 - 1414

Moran O.
The biophysics, biochemistry and physiology of CFTR
Cellular and Molecular Life Sciences 2017; 74: 1 - 2

Moran O.
The gating of the CFTR channel
Cellular and Molecular Life Sciences 2017; 74: 85 - 92

Negada A., El Hiani Y., Cowley EA., Linsdell P.
Contribution of a leucine residue in the first transmembrane segment to the selectivity filter region in the CFTR chloride channel
Biochimica et Biophysica Acta-Subcellular Biology 2017; 1859: 1049 - 1058

Philippe R., Antigny F., Buscaglia P., Kourtidis A., Scirpo R., Amenduni M., Ghebri P., Cadamu M., Spirlì C., Anastasiadis PZ., Strazzabosco M.
The Cystic Fibrosis Transmembrane Conductance Regulator Impairs Intestinal Oxalate Secretion
Journal of the American Society of Nephrology 2017; 28: 242 - 249

Rauhl R., Hoener C., Korbmacher C.
delta beta gamma-ENaC is inhibited by CFTR but stimulated by cAMP in Xenopus laevis oocytes
American Journal of Physiology-Cellular and Molecular Physiology 2017; 312: L277 - L287

Rowe SM.
A little CFTR can change a lot
Lancet Respiratory Medicine 2017; 5: 86 - 87

Saint-Criq V., Gray MA.
Role of CFTR in epithelial physiology
Cellular and Molecular Life Sciences 2017; 74: 93 - 115

Salinas DB., Kang L., Azn C., Quinton P.
Low Beta-Adrenergic Sweat Responses in Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome Children
Pediatric Allergy Immunology and Pulmology 2017; 30: 2 - 6
Stephenson AL., Sykes J., Stanojevic S., Quon BS., Marshall BC., Petren K., Ostrenja J., Fink AK., Elbert A., Goss CH. Survival Comparison of Patients with Cystic Fibrosis in Canada and the United States A Population-Based Cohort Study
Annals of Internal Medicine 2017; 165: 537 - +

Tumin D., Li SS., Kopp BT., Kirkby SE., Tobias JD., Morgan WJ., Hayes D. The effect of the affordable care act dependent coverage provision on patients with cystic fibrosis
Pediatric Pulmonology 2017; 52: 458 - 466

Weber HC., Robinson PF., Saxby N., Beggs SA., Els I., Ehrlich RI. Do children with cystic fibrosis receiving outreach care have poorer clinical outcomes than those treated at a specialist cystic fibrosis centre?
Australian Journal of Rural Health 2017; 25: 34 - 41

Yadav H., Lim KG. Chronic cough with normal sweat chloride: Phenotypic descriptions of two rare cystic fibrosis genotypes
Respiratory Medicine Case Reports 2016; 17: 17 - 19

Databases & Registries

Buzzetti R., Salvatore D. Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared?
American Journal of Respiratory and Critical Care Medicine 2017; 195: 404 - 405
Pediatric Pulmonology 2017; 52: 390 - 398
Sawicki GS., Konstan MW. Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared? Reply
American Journal of Respiratory and Critical Care Medicine 2017; 195: 405 - 406

Diabetes

Lalayianis AD., Thompson C., Malcomson R., Milford DV. Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case
Respiratory Medicine Case Reports 2016; 19: 58 - 60
Mainguy C., Bellon G., Delaup V., Ginoux T., Kassai-Koupaï B., Mazur S., Rabilloud M., Remontet L., Reix P. Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
Journal of Pediatric Endocrinology & Metabolism 2017; 30: 27 - 35
Montanini L., Smerieri A., Gulli M., Cirillo F., Pisi G., Sartori C., Amari S., Bernasconi S., Marmiroli N., Street ME. miR-146a, miR-155, miR-370 and miR-708 are CFTR-dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs
Journal of Clinical Endocrinology & Metabolism 2016; 101: 4955 - 4963

Diagnosis

Aralica M., Krieza JI. Evaluating performance in sweat testing in medical biochemistry laboratories in Croatia
Biochimia Medica 2017; 27: 122 - 130
Dupuis EC., Sperou AJ., Fiorillo L. Cover Image: Aquagenic wrinkling of the palms: a clue to underlying cystic fibrosis heterozygosity
British Journal of Dermatology 2017; 176: 553 - 554

Farrell PM., White TB., Derichs N., Castellani C., Rosenstein RJ. Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned
Journal of Pediatrics 2017; 181:
Journal of Pediatrics 2017; 181:
Journal of Pediatrics 2017; 181:
Felicio V., Ramalho AS., Igreja S., Amaral MD. mRNA-based detection of rare CFTR mutations improves genetic diagnosis of cystic fibrosis in populations with high genetic heterogeneity
Clinical Genetics 2017; 91: 476 - 481
Journal of Cystic Fibrosis 2017; 16: 198 - 206
Chemical Science 2017; 8: 550 - 558
Ratkiewicz M., Pastore M., Mceoy KS., Thompson R., Hayes D., Sheikh SI. Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis
Ren CL., Borowitz DS., Gonska T., Howenstine MS., Levy H., Massie J., Milla C., Munck A., Southern KW. Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis
Journal of Pediatrics 2017; 181:
Servidoni MF., Gomez CCS., Marson FAL., Toro AADC., Ribeiro MAGD., Ribeiro JD., Ribeiro AF. Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of Sao Paulo
Jornal Brasileiro de Pneumologia 2017; 43: 121 - 128
Sosnas PR., White TB., Farrell PM., Ren CL., Derichs N., Howenstine MS., Nick JA., De Boeck K. Diagnosis of Cystic Fibrosis in Nonscreened Populations
Journal of Pediatrics 2017; 181:
Straniero L., Solda G., Costantino L., Seia M., Melotti P., Colombo C., Assella R., Duga S. Whole-gene CFTR sequencing combined with digital RT-PCR improves genetic diagnosis of cystic fibrosis
Journal of Human Genetics 2016; 61: 977 - 984
Thomas JM., Durack A., Sterling A., Todd PM., Tomson N. Aquagenic wrinkling of the palms: a diagnostic clue to cystic fibrosis carrier status and non-classic disease
Lancet 2017; 389: 846
Tümmler B. Variability of sweat chloride - A never ending story
Epidemiology

Burget PR.
Epidemiological trends of cystic fibrosis in France: 10-year perspective
Archives de Pediatrie 2016; 23:

A Clinical and Molecular Survey of 62 Cystic Fibrosis Patients from Umbria (Central Italy) Disclosing a High Frequency (2.4%) of the 2184insA Allele: Implications for Screening

Stewart C., Pepper MS.
Cystic Fibrosis in the African Diaspora

Exercise

Beaudoin N., Bouvet GF., Coriati A., Rabasa-Lhoret R., Berthiaume Y.
Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis

Biel C., Summermatter S., Boutellier U., Moeller A.
Respiratory Muscle Training Improves Respiratory Muscle Endurance But Not Exercise Tolerance in Children With Cystic Fibrosis
Pediatric Pulmonology 2017; 52: 333 - 336

Donadio MVF., Heinzmann JP., Vendrusculo FM., Frasson PXL., Maristela PJ.
Six-Minute Walk Test Results Predict Risk of Hospitalization for Youths with Cystic Fibrosis: A 5-Year Follow-Up Study
Journal of Pediatrics 2017; 182: 204 - 209

Karapangiotis S., Gambazza S., Brivio A., D’Abrosca F., Colomba C.
Ventilatory Limitation and Dynamic Hyperinflation during Exercise Testing in Cystic Fibrosis
Pediatric Pulmonology 2017; 52: 29 - 33

Okuro RT., Ribeiro MAGD., Ribeiro JD., Minsky RC., Schivinski CIS.
Alternative Indexes to Estimate the Functional Capacity From the 6-Minute Walk Test in Children and Adolescents With Cystic Fibrosis
Respiratory Care 2017; 62: 324 - 332

Smith L., Reilly CC., MacBean V., Jolley CJ., Elston C., Moxham J., Rafferty GF.
Physiological markers of exercise capacity and lung disease severity in cystic fibrosis
Respirology 2017; 22: 714 - 720

Gene Therapy

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Thorax 2017; 72: 137 - 147

Palmer DJ., Grove NC., Ing J., Crane AM., Venken K., Davis BR., Ng P.
Homology Requirements for Efficient, Footprintless Gene Editing at the CFTR Locus in Human iPSCs with Helper-dependent Adenoviral Vectors
Molecular Therapy-nucleic Acids 2016; 5: ArNo: e372

Villate-Belita L., Zarate J., Puras G., Pedraz JL.
Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis
Drug Development and Industrial Pharmacy 2017; 43: 1071 - 1081

Weber P., Konneh M., Jeffrey P., Overington J.
Gene Therapy: Right Here, Right Now. Highlights from the Society for Medicines Research Meeting
Drugs of the Future 2017; 42: 251 - 256
General Review
Zemanick ET., Ong T., Daines CL., Dellon EP., Muhlebach MS., Esther CR.
Highlights from the 2015 North American Cystic Fibrosis Conference
Pediatric Pulmonology 2016; 51: 650 - 657

Genetics
Abdullahi LI., Evans JR., Wang TT., Ford AA., Makhom AM., Nguyen K., Coldley RD., Griffith JD., Davis CW., Ballard ST., Kesimer M.
Defective postsecretory maturation of MUCSB mucin in cystic fibrosis airways
JCI Insight 2017; 2: 6:e98752
AbdulWahab A., Abushahin A., Allangawi M., Chandra P., Rahman MOA., Soliman A.
Serum zinc concentration in cystic fibrosis patients with CFTR II343V mutation associated with pancreatic sufficiency
Clinical Respiratory Journal 2017; 11: 305 - 310
Celestino-Sopher PBS., Simpsoon E., Brink DT., Lynnes TC., Dhouhy S., Vatta M., Yeley J., Brown C., Bai SC.
Intragenic CFTR Duplication and 5T/12TG Variant in a Patient with Non-Classic Cystic Fibrosis
Scientific Reports 2016; 6: ArNo: 38776
de Souza DAS., Fauce FR., de Andrade RB., Santana MA., de Souza ELS., Reis FJC., Pereira-Ferrari L., Sotomaioar VS., Culpi L., Phillips JA., Raskin S.
Cystic fibrosis in Afro-Brazilians: XK haplotypes analysis supports the European origin of p.F508del mutation
Genetica 2017: 145: 19 - 25
Karim N., Alibakshi R.
Molecular analysis of exon 13 of cystic fibrosis patients in Middle East: High frequency of K710X mutation
Meta Gene 2017; 11: 305 - 310
Kayran YU., Ozkan-Arikosyal D., Toplaya SN., Kaymaz BT., Can BK.
Cystic Fibrosis Mutation Detection with SPR Biosensor in Real Samples via Multiple Surfaces Binding Method
Combinatorial Chemistry & High Throughput Screening 2017; 20: 56 - 63
Leung GKC., Ying DG., Mak CCY., Chen XY., Xu WY., Yeung KS., Wong WL., Chu YYW., Mok GTK., Chau CSK., McLuskey J., Ong WPT., Leong HY., Chan KYK., Yang WL., Chen JHL., Li AM., Sham PSC., Lau YL., Chung BHY., Lee SL.
CFTR founder mutation causes protein trafficking defects in Chinese patients with cystic fibrosis
Molecular Genetics & Genomic Medicine 2017; 5: 40 - 49
DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis
Clinical Epigenetics 2017: 9: ArNo: 19
Pique L., Graham S., Pearl M., Kharrazi M., Schrijver I.
Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients
Genetics in Medicine 2017; 19: 36 - 44
Soe K., Gregoire-Bottex MM.
A rare CFTR mutation associated with severe disease progression in a 10-year-old Hispanic patient
Clinical Case Reports 2017; 5: 139 - 144
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics
Human Molecular Genetics 2016; 25: 4590 - 4600
Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles
Journal of Medical Genetics 2017; 54: 224 - 235
Trouve P., Genin E., Ferec C.
in silico search for modifier genes associated with pancreatic and liver disease in Cystic Fibrosis
Zheng BY., Cao L.
Differences in Gene Mutations Between Chinese and Caucasian Cystic Fibrosis Patients
Pediatric Pulmonology 2017; 52: E11 - E14

Growth & Development
Decorte N., Gruet M., Camara B., Quentant S., Mely L., Vallier JM., Verge S., Wuyama B.
Absence of cell mass muscle metabolism alterations in active cystic fibrosis adults with mild to moderate lung disease
Journal of Cystic Fibrosis 2017; 16: 98 - 106
El Attar MM., Azab NM., Hamed DHE., Tawfik ASA.
Growth assessment in Egyptian children with cystic fibrosis: A single center study
Egyptian Pediatric Association Gazette 2017; 65: 21 - 24
Impaired rib bone mass and quality in end-stage cystic fibrosis patients
Bone 2017; 98: 9 - 17
Woestenenk JW., Gulmans VAM., van der Ent CCK., Houwen RHI.
Height Assessment in the Dutch-Origin Pediatric Cystic Fibrosis Population
Nutrition in Clinical Practice 2017; 32: 130 - 132

Immunology & Inflammation
Assani K., Shrestha CL., Robledo-Avila F., Rajaram MV., Partida-Sanchez S., Schlesinger LS., Kopp BT.
Human Cystic Fibrosis Macrophages Have Defective Calcium-Dependent Protein Kinase C Activation of the NADPH Oxidase, an Effect Augmented by Burkholderia cenocepacia
Journal of Immunology 2017; 198: 1985 - 1994
Dickerhof N., Turner R., Khalilova I., Fantino E., Sly PD., Kettle AJ.
Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease
Journal of Cystic Fibrosis 2017; 16: 214 - 221
Airway inflammation in mild cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 107 - 115
Esther CR., Turkovic L., Rosenow T., Muhlebach MS., Boucher RC., Ranganathan S., Stick SM.
Metabolic biomarkers predictive of early structural lung disease in cystic fibrosis
European Respiratory Journal 2016; 48: 1612 - 1621
Forrester DL., Barr HL., Fogarty A., Knox A.
sTREM-1 is elevated in cystic fibrosis and correlates with proteases
Pediatric Pulmonology 2017; 52: 467 - 471

Hair PS., Sass LA., Krishna NK., Cunnion KM.
Inhibition of Myeloperoxidase Activity in Cystic Fibrosis Sputum by Peptide Inhibitor of Complement C1 (PIC1)

Hair PS., Sass LA., Vaifedan T., Shah TA., Krishna NK., Cunnion KM.
Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity

Kerley CP., Kilbride E., Greally P., Elnaziz B.
Dietary Nitrates Acutely and Markedly Increased Exhaled Nitric Oxide in a Cystic Fibrosis Case
Clinical Medicine & Research 2016; 14: 151 - 155

End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis
Respiratory Research 2017; 18: ArNo: 10

A novel monoclonal antibody suitable for the detection of Pseudomonas aeruginosa Infection
JCM 2017; 31: 1891 - 1902

Lin CK., Kazmierczak BL.
Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection

Lutkewosmann S., Warsinke A., Tschope W., Eichler R., Hanack K.
A novel monoclonal antibody suitable for the detection of leukotriene B4
Biochemical and Biophysical Research Communications 2017; 482: 1054 - 1059

Martinez-Aleman SR., Campos-Garcia L., Palma-Nicolas JP., Hernandez-Bello R., Gonzalez GM., Sanchez-Gonzalez A.
Understanding the Entanglement: Neutrophil Extracellular Traps (NETs) in Cystic Fibrosis
Frontiers in Cellular and Infection Microbiology 2017; 7: ArNo: 104

Mil-Homens D., Pinto SN., Matos RG., Araaiano C., Fialho AM.
Burkholderia cenocepacia KS6-2 trimeric autotransporter adhesin BcaA binds TNFR1 and contributes to induce airway inflammation
Cellular Microbiology 2017; 19: 4:UNSP e12677

An antisense peptide nucleic acid against Pseudomonas aeruginosa inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system

Montgomery ST., Mall MA., Kicic A., Stick SM.
Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies
European Respiratory Journal 2017; 49: 1:1600903

A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis
Nature Communications 2017; 8: ArNo: 14017

Rada B.
Interactions between Neutrophils and Pseudomonas aeruginos in Cystic Fibrosis
Pathogens 2017; 6: 1:10

Ribeiro CMP., Lubambo BA.
Role of IRE1 alpha/XBP-1 in Cystic Fibrosis Airway Inflammation
International Journal of Molecular Sciences 2017; 18: 1:118

Sharma A., Kirtkpatrick G., Chen V., Skolnik K., Holland Z., Wilcox P., Quon BS.
Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

Shmarina G., Pukhalsky A., Avakian L., Semykin S., Pukhalskaya D., Alloshkin V.
Steady-State Therapy with Azithromycin or Low-Dose Prednisolone in Pardiatric Cystic Fibrosis Patients: Inflammatory Markers and Disease Progression
International Archives of Allergy and Immunology 2017; 172: 45 - 54

Stanton BA.
Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response
American Journal of Physiology-cell Physiology 2017; 312: C357 - C366

Zeitlin PL., Diener-West M., Callahan KA., Lee S., Talbot CC., Pollard B., Boyle MP., Lechtzin N.
Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding

Liver Disease

Correlation of Transient Elastography with Severity of Cystic Fibrosis-related Liver Disease
Journal of Pediatric Gastroenterology and Nutrition 2017; 64: 505 - 513

Debray D., Mas E., Munck A., Gerardin M., Clouzeau H.
Liver disease, gastrointestinal complications, nutritional management and feeding disorders in pediatric cystic fibrosis
Archives of Pediatric 2016; 23:

Microbiology

Abd Alrahman M., Yoon SS.
Identification of essential genes of Pseudomonas aeruginosa for its growth in airway mucus
Journal of Microbiology 2017; 55: 68 - 74

Agarwal R., Bansal S., Chakrabarti A.
Are allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions?
Clinical Medicine & Research 2016; 14: 151

Agarwal R., Dua D., Choudhary H., Aggarwal AN., Sehgal BS., Dhoooria S., Garg M., Behera D., Chakrabarti A.
Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis
Mycoses 2017; 60: 33 - 39
APMIS 2017; 125: 272 - 275

Haiby N. A short history of microbial biofilms and biofilm infections

APMIS 2017; 125: 272 - 275

Haiby N., Bjarnsholt T., Moser C., Jensen PO., Kolpen M., Qvist T., Annaes K., Pressler T., Skov M., Ciofu O.

Diagnosis of biofilm infections in cystic fibrosis patients

APMIS 2017; 125: 339 - 343

Hong G., Miller HB., Allgood S., Lee R., Lechtzin N., Zhang SX.

Use of Selective Fungal Culture Media Increases Rates of Detection of Fungi in the Respiratory Tract of Cystic Fibrosis Patients

Journal of Clinical Microbiology 2017; 55: 1122 - 1130

Hotterbeeks A., Kumar-Singh S., Goossens H., Malhotra-Kumar S.

In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.

Frontiers in Cellular and Infection Microbiology 2017; 7: ArNo: 106

Janahi IA., Rehman A., Al-Naimi AR.

Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis


Jensen PO., Kolpen M., Kragh KN., Kuhl M.

Microenvironmental characteristics and physiology of biofilms in chronic infections of CF patients are strongly affected by the host immune response

APMIS 2017; 125: 276 - 288

Lee AHY., Filibotte S., Sinha S., Paiero A., Ehrlich RL., Balashov S., Ehrlich GD., Zlosnik JEA., Mell JC., Nislow C.

Phenotypic diversity and genotypic flexibility of Burkholderia cenocepacia during long-term chronic infection of cystic fibrosis lungs

Genome Research 2017; 27: 650 - 662

Li C., Wu YQ., Riehle A., Ma J., Kamler M., Gulbins E., Grassme H.

Staphylococcus aureus Survives in Cystic Fibrosis Macrophages, Forming a Reservoir for Chronic Pneumonia Infection and Immunity 2017; 85: 5:e00883-16

Lightly TJ., Phung RR., Sorensen JL., Cardona ST.

Synthetic cystic fibrosis sputum medium diminishes Burkholderia cenocepacia antifungal activity against Aspergillus fumigatus independently of phenylacetic acid production

Canadian Journal of Microbiology 2017; 63: 427 - 438

Limoli DH., Whitfield GB., Kitau T., Ivey ML., Davis MR., Grahl N., Hogan DA., Rahme LG., Howell PL., O'Toole GA., Goldberg JB.

Pseudomonas aeruginosa Alginate Overproduction Promotes Coexistence with Staphylococcus aureus in a Model of Cystic Fibrosis Respiratory Infection

mBio 2017; 8: 2:e00186-17

Lopes SP., Carvalho DT., Pereira MO., Azevedo NF.

Discriminating typical and atypical cystic fibrosis-related bacteria by multiplex PNA-FISH

Biotechnology and Bioengineering 2017; 114: 355 - 367

Magalhaes AP., Lopes SP., Pereira MO.

Insights into Cystic Fibrosis Polymicrobial Consortia: The Role of Species Interactions in Biofilm Development, Phenotype, and Response to In Use Antibiotics

Frontiers in Microbiology 2017; 7: ArNo: 2146

Malone M., Goeres DL., Gosbell I., Vickery K., Jensen S., Stoodley P.

Approaches to biofilm-associated infections: the need for standardized and relevant biofilm methods for clinical applications

Marguet C., Lemee L., Morisse-Pradier H., Coudere L.
Infections in Cystic Fibrosis: Up-to-date
Archives de Pediatrie 2016; 23:

oMartina PF., Martínez M., Frada G., Alvarez F.,
Leguizamón L., Prieto C., Barrias C., Bettiol M., Lagares A.,
Bosch A., Ferreras J., Von Specht M.
First time identification of Pandoraea spoutorum from a patient
with cystic fibrosis in Argentina: a case report
BMC Pulmonary Medicine 2017; 17; ArNo: 33

Miragoli F., Federici S., Ferrari S., Minuti A., Rebecchi A.,
Bruzzese E., Bucigrossi V., Guarino A., Callegari ML.
Impact of cystic fibrosis disease on archaea and bacteria
composition of gut microbiota
FEMS Microbiology Ecology 2017; 93: 2:230

Moore JE., Mastoridis P.
Clinical implications of Pseudomonas aeruginosa location in the
lungs of patients with cystic fibrosis
Journal of Clinical Pharmacy and Therapeutics 2017; 42: 259 - 267

Moradali MF., Ghods S., Rehm BHA.
Activation Mechanism and Cellular Localization of Membrane-Anchored
Alginate Polymerase in Pseudomonas aeruginosa

Moser C., Pedersen HT., Lerche CJ., Kolpen M., Line L.,
Thomsen K., Hoiby N., Jensen PO.
Biofilms and host response - helpful or harmful
APMIS 2017; 125: 320 - 338

Nadell CD., Ricaurte D., van J., Drescher K., Bassler BL.
Flow environment and matrix structure interact to determine
spatial competition in Pseudomonas aeruginosa biofilms
Elife 2017; 6; ArNo: e21855

Nazik H., Ross RB., Karna V., Moss RB., Clemons KV., Banaei N.,
Einarsson GG., Elborn JS., Martin SL.
Are Cystic Fibrosis Aspergillus fumigatus fumigatus Isolates Different?
Intermicrobial Interactions with Pseudomonas
Mycopathologia 2017; 182: 315 - 318

Nguyen LDN., Deschagt P., Merlin S., Loywick A.,
Audebert C., Van Daele S., Viscogliosi E., Vaneechoutte M.,
Delhaes L.
Effects of Propidium Monoxide (PMA) Treatment on
Mycobiome and Bacteriome Analysis of Cystic Fibrosis
Airways during Exacerbation

O'Brien S., Williams D., Fothergill JL., Paterson S.,
Winstanley C., Brochhurst MA.
High virulence sub-populations in Pseudomonas aeruginosa
long-term cystic fibrosis airway infection
BMC Microbiology 2017; 17: ArNo: 30

Pages-Monteiro L., Marti R., Commun C., Alliot N., Bardel C.,
Meugnier H., Perouse-Dumont L., Reix P., Durieu L., Durupt S., Vandenbroucke F., Freny J., Cournoyer B.,
Doleans-Jordheim A.
Strong incidence of Pseudomonas aeruginosa on bacterial rrs
and ITS genetic structures of cystic fibrosis sputa

Papp-Wallace KM., Becka SA., Taracila MA., Zeiser ET.,
Gatta JA., Lipuma JJ., Bonomo RA.
Exploring the Role of the Omega-Loop in the Evolution of
Ceftazidime Resistance in the PenA beta-Lactamase from
Burkholderia multivorans, an Important Cystic Fibrosis Pathogen
Antimicrobial Agents and Chemotherapy 2017; 61: 2:UNSP e01941-

Peeters C., Cooper VS., Hatcher PJ., Verheyde B., Carlier A.,
Vandamme P.
Comparative genomics of Burkholderia multivorans, a
ubiquitous pathogen with a highly conserved genomic structure

Pereira RHV., Leao RS., Carvalho-Assaf AP., Albano RM.,
Rodrigues ERA., Fiminda MC., Folescu TW., Plotkowski MC., Bernardo VG., Marques EA.
Patterns of virulence factor expression and antimicrobial
resistance in Achromobacter xylosoxidans and Achromobacter
ruhlandii isolates from patients with cystic fibrosis
Epidemiology and Infection 2017; 145: 600 - 606

Piccolo F., Tai AS., He H., Mulrennan S., Bell S., Ryan G.
Closstrikid infection in cystic fibrosis: an uncommon
but life-threatening complication
Respirology Case Reports 2017; 5: 1:UNSP e00204

Plongala R., Preece CL., Perry JD., Gilligan PH.
Evaluation of RGM Medium for Isolation of Nontuberculous
Mycobacteria from Respiratory Samples from Patients with
Cystic Fibrosis in the United States
Journal of Clinical Microbiology 2017; 55: 1469 - 1477

Prevaes SMPI., Piters WAAD., de Winter-de Groot KM.,
Janssen HM., Tranper-Stranders GA., Chu MLJN.,
Tiddens HA., van Westreenen M., van der Ent CK., Sanders EAM., Bogaert D.
Concordance between upper and lower airway microbiota in
infants with cystic fibrosis
European Respiratory Journal 2017; 49: 3:1602255

Qvist T., Pressler T., Katzenstein TL., Hoiby N., Collins MT.
Evaluation of a Bovine Antibody Test for Diagnosing
Mycobacterium avium Complex in Patients with Cystic Fibrosis
Pediatric Pulmonology 2017; 52: 34 - 40

Raclavsky V., Stromerova N., Safarova D., Bardon J.,
Zatoukal J., Zapalika M., Jakubeck P., Navratilova L.,
Novotny R.
McRAPD unlike MALDI-TOF MS is a suitable candidate for
routine discrimination of new Haemophilus influenzae strain
acquisition in chronic obstructive pulmonary disease (COPD)
and cystic fibrosis
Biomedical Papers-Olomouc 2016; 160: 503 - 511

Regan KH., Bhatt J.
Eradiation therapy for Burkholderia cepacia complex in people
with cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 11:CD009876

Reihill JA., Moreland M., Jarvis GE., McDowell A.,
Einarsson GG., Elborn JS., Martin SL.
Bacterial proteases and haemostasis dysregulation in the CF
lung
Journal of Cystic Fibrosis 2017; 16: 49 - 57

Rodrigues ERA., Rocha GA., Ferreira AG., Leao RS.,
Albano RM., Marques EA.
Draft genome sequences of four Achromobacter ruhlandii
isolates from patients with cystic fibrosis
Memorias do Instituto Oswaldo Cruz 2016; 111: 777 - 780

Roussel L., Rousseau S.
Exposure of airway epithelial cells to Pseudomonas aeruginosa
biofilm-derived quorum sensing molecules decrease the activity
of the anti-oxidant response element bound by NRF2
Biochemical and Biophysical Research Communications 2017; 483: 829 - 833

Rowan NR., Wang EW., Kanaan A., Sahu N., Williams JV.,
Phillips CD., Lee SE.
Respiratory viral detection in the paranasal sinuses of patients
with cystic fibrosis
American Journal of Rhinology & Allergy 2017; 31: 105 - 113

Rutter WC., Burgess DR., Burgess DS.
Increasing Incidence of Multidrug Resistance among Cystic
Fibrosis Respiratory Bacterial Isolates
Microbial Drug Resistance 2017; 23: 51
Schaefers MM., Liao TL., Boisvert NM., Roux D., Yoder-Himes D., Priebe GP. 
An Oxygen-Sensing Two-Component System in the 
Burkholderia cepacia Complex Regulates Biofilm, Intracellular 
Invasion, and Pathogenicity 
PloS Pathogens 2017; 13: e1006116

Schwartbeck B., Birtel J., Treffon J., Langhanki L., 
Mellmann A., Kade D., Kahl J., Hirschhausen N., Neumann 
C., Lee JC., Gotz F., Rohde H., Henke H., Kuster P., Peters 
G., Kahl BC. 
Dynamic in vivo mutations within the icp operon during 
persistence of Staphylococcus aureus in the Airways of cystic fibrosis 
patients 
PloS Pathogens 2016; 12: e1006204

Schwarz C., Brandt C., Antweiler E., Kranisch A., Staab D., 
Schmitt-Grohe S., Fischer R., Hartl D., Thronicke A., 
Tintelnot K. 
Prospective multicenter German study on pulmonary 
colonization with Scedosporium /Lomentospora species in 
cystic fibrosis: Epidemiology and new association factors 
PloS One 2017; 12: e0171455

Sharma A., Xu YQ., Sung B., Vincent CT., Worgall T., 
Worgall S. 
Regulation of the Cox sackie and adenovirus receptor expression is 
dependent on cystic fibrosis transmembrane regulator in 
airway epithelial cells 
Cellular Microbiology 2017; 19: 2-UNSP e12654

Sherrard LJ., Tai AS., Wee BA., Ramsay KA., Kidd TJ., 
Ben Zakour NL., Whiley DM., Beaton SA., Bell SC. 
Within-host whole genome analysis of an antibiotic resistant 
Pseudomonas aeruginosa strain sub-type in cystic fibrosis 
PloS One 2017; 12: 3:e0172179

Somayaji R., Lam JC., Surette MG., Waddell B., Rabin HR., 
Sibley CD., Purigliha S., Parkins MD. 
Long-term clinical outcomes of ‘Prairie Epidemic Strain’ 
Pseudomonas aeruginosa infection in adults with cystic fibrosis 
Thorax 2017; 72: 333 - 339

Sonderholm M., Kragh KN., Koren K., Jakobsen TH., 
Darch SE., Alhede M., Jensen PO., Whiteley M., Kuhl M., 
Bjarnsholt T. 
Pseudomonas aeruginosa Aggregate Formation in an Alginate 
Bead Model System Exhibits In Vivo Like Characteristics 
Applied and Environmental Microbiology 2017; 83: 9-UNSP 
e00113- 

Soussa SA., Feliciano JR., Pita T., Guerreiro SL., Leitao JH. 
Burkholderia cepacia Complex Regulation of Virulence Gene 
Expression: A Review 
Genes 2017; 8: 1:43

Stobbelaar K., Van Hoorenbeeck K., Lequesne M., De Dooy 
J., Ho E., Vlieghe E., Ieven M., Verhulst S. 
Sepsis Caused by Achromobacter Xylosoxidans in a Child with 
Cystic Fibrosis and Severe Lung Disease 
American Journal of Case Reports 2016; 17: 562 - 566

Viberg LT., Sarovich DS., Kidd TJ., Geake JB., Bell SC., 
Currie RJ., Price EP. 
Within-Host Evolution of Burkholderia pseudomallei during 
Chronic Infection of Seven Australasian Cystic Fibrosis Patients 
mdBio 2017; 8: e00156-17

Viel M., Hubert D., Burgel PR., Genin E., Honore L., 
Martinez B., Gaitech N., Chapron J., Kanaan R., Dusser D., 
Girodon E., Bienvenu T. 
DCTN4 as a modifier of chronic Pseudomonas aeruginosa 
infected in cystic fibrosis 
Clinical Respiratory Journal 2016; 10: 777 - 783

Waite RD., Qureshi MR., Whitey RA. 
Modulation of behaviour and virulence of a high alginate 
expressing Pseudomonas aeruginosa strain from cystic fibrosis 
by oral commensal bacterium Streptococcus anginosus 
PloS One 2017; 12: 3:e0173741

Waters V., Ratjen F. 
Antibiotic treatment for nontuberculous mycobacteria lung 
Infection in people with cystic fibrosis 
Cochrane Database of Systematic Reviews 2016: : 12:CD010004

Wettlaufer J., Klingel M., Yao Y., Stanojevic S., Tullis E., 
Ratjen F., Waters V. 
Longitudinal study of Stenotrophomonas maltophilia antibody 
levels and outcomes in cystic fibrosis patients 

Whelan FJ., Heirali AA., Rossi L., Rabin HR., Parkins MD., 
Surette MG. 
Longitudinal sampling of the lung microbiota in individuals 
with cystic fibrosis 
PloS One 2017; 12: 3:e0172811

Nutrition

Alvarez JA., Chong EY., Walker DL., Chandler JD., 
Michalski ES., Grossmann RE., Uppal K., Li S., Frediani 
JK., Tirouvanziam R., Tran VT., Tanggricha V., Jones DP., 
Ziegler TR. 
Plasma metabolomics in adults with cystic fibrosis during a 
pulmonary exacerbation: A pilot randomized study of high-dose 
vitamin D-3 administration 
Metabolism - Clinical and Experimental 2017; 70: 31 - 41

Anderson JL., Miles C., Tierney AC. 
Effect of probiotics on respiratory, gastrointestinal and 
nutritional outcomes in patients with cystic fibrosis: A 
Systematic review 
Journal of Cystic Fibrosis 2017; 16: 186 - 197

Garavaglia L., Duncan C., Toucheque M., Farley A., Moffett 
KS. 
A Quality Improvement Initiative to Improve Patient Adherence 
to Vitamin Supplementation in Cystic Fibrosis 
Journal of Pediatric Gastroenterology and Nutrition 2017; 64: 
292 - 295

Garriga M., Horrisberger A., de las Heras AR., Catalan N., 
Fernandez G., Suarez M., Porras N., Monje L. 
Clinical Practice Guidelines for nutritional management of 
Cystic Fibrosis patients (GPC-CF) 
Revisa Espanola de Nutricion Humana Y Dietetica 2017; 21: 
74 - 97

Konstan MW., Pasta DJ., Wagener JS., VanDevanter DR., 
Morgan WJ. 
BMI fails to identify poor nutritional status in stunted children 
with CF 

Krylova NA., Amelina EL., Krasovsky SA. 
Nutritional status in patients with cystic fibrosis: Possibilities of 
correction 
Terapevticheskii Arkhiv 2016; 88: 163 - 167

Moukarzel S., Dyer RA., Innis SM. 
Clinical impact of vitamin D treatment 
Journal of Cystic Fibrosis 2017; 16: 148 - 149

Nutritional Practice Guidelines for nutritional management of 
cystic fibrosis: A systematic review 
Nutrients 2017; 9: 295

Pincikova T., Paquin D., Sandberg JK., Flodstrom- 
Tullberg M., Hjelte L. 
Clinical impact of vitamin D treatment in cystic fibrosis: a pilot 
randomized, controlled trial 

Ypez ANB., Torres JFM. 
Clinical case: Nutritional and Therapeutic Intervention Post 
Gastric Bypass in a patient with Cystic Fibrosis 
Nutricion Clinica Y Dietetica Hospitalaria 2017; 37: 183 - 188
Oral Aspects
Alkhateeb AA., Manel LA., Presland RB., Rothen ML., Chi DL.
Unstimulated Saliva-Related Caries Risk Factors in Individuals with Cystic Fibrosis: A Cross-Sectional Analysis of Unstimulated Salivary Flow, pH, and Buffering Capacity
Caries Research 2017; 51: 1 - 6

Physiotherapy
Corten L., Morrow BM.
Autogenic Drainage in Children With Cystic Fibrosis
Pediatric Physical Therapy 2017; 29: 106 - 117

Dwyer TJ., Zainulldin R., Daviskas E., Bye PTP., Alison JA.
Effects of treadmill exercise versus Flutter (R) on respiratory flow and spumum properties in adults with cystic fibrosis: a randomised, controlled, cross-over trial
BMC Pulmonary Medicine 2017; 17: ArNo: 14

Grose-Onnebrink J., Mellies U., Olivier M., Werner C., Stehling F.
Chest physiotherapy can affect the lung clearance index in cystic fibrosis patients
Pediatric Pulmonology 2017; 52: 625 - 631

Mckoy NA., Wilson LM., Saldanha JH., Odelola OA., Robinson KA.
Active cycle of breathing technique for cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 7:CD007862

Van Fleet H., Dunn DK., McNinch NL., Volsko TA.
Evaluation of Functional Characteristics of 4 Oscillatory Positive Pressure Devices in a Simulated Cystic Fibrosis Model
Respiratory Care 2017; 62: 451 - 458

Psychosocial
Barker H., Moses J., O’Leary C.
‘I’ve got to prioritise’: being a parent with cystic fibrosis
Psychology Health & Medicine 2017; 22: 744 - 752

Beinke K., O’Callaghan F., Morrissey S.
Illness Perceptions of Cystic Fibrosis: A Comparison of Young Adults with CF and Same-Aged Peers
Behavioral Medicine 2017; 43: 40 - 46

Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP)
BMJ Open 2017; 7: :3:e014931

Gardner AJ., Gray AL., Self S., Wagener JS.
Supporting cystic fibrosis patients to improve adherence in cystic fibrosis: a qualitative practice assessment and quality improvement initiative
Patient Preference and Adherence 2017; 11: 761 - 767

Gur M., Nir V., Teleshov A., Bar-Yousef R., Manor E., Diab G., Bentur L.
The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: A pilot study
Journal of Telemedicine and Telecare 2017; 23: 489 - 493

Hochwalder J., Brucefors AB., Hjette L.
Psychometric evaluation of the Swedish translation of the revised Cystic Fibrosis Questionnaire in adults
Upsala Journal of Medical Sciences 2017; 122: 61 - 66

Hoo ZH., Campbell MJ., Curley R., Wildman MJ.
An empirical method to cluster objective nebulizer adherence data among adults with cystic fibrosis
Patient Preference and Adherence 2017; 11: 631 - 642

Pulmonology
Blackmon RL., Kreda SM., Sears PR., Chapman BS., Hill DB., Tracy JB., Ostrowski LE., Oldenburg AL.
Direct monitoring of pulmonary disease treatment biomarkers using plasmonic gold nanodisks with diffusion-sensitive OCT
Nanoscale 2017; 9: 4907 - 4917

Bock JM., Schien M., Fisch B., Benecke K., Fisc M., Kolowicz H., Debecker A., De Peter W., Tone C., Mainz JG.
Importance to question sinonasal symptoms and to perform rhinoscopy and rhinomanometry in cystic fibrosis patients
Pediatric Pulmonology 2017; 52: 167 - 176

Brook CD., Maxfield AZ., Ahmed H., Sedaghat AR., Holbrook EH., Gray ST.
Factors influencing the need for endoscopic sinus surgery in adult patients with cystic fibrosis
American Journal of Rhinology & Allergy 2017; 31: 44 - 47

Chatinel R., Anne-Arachard D., Murriss-Espin M., Thiriet M., Poncet P.
Numerical and experimental investigation of mucociliary clearance breakdown in cystic fibrosis
Journal of Biomechanics 2017; 53: 56 - 63

Cogen JD., Oron AP., Gibson RL., Hoffman LR., Kronman MP., Ong T., Rosenfeld M.
Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations
Pediatrics 2017; 139: 2:e20162642

Lin AHA., Kendrick JG., Wilcox PG., Quon BS.
Patient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis
Patient Preference and Adherence 2017; 11: 691 - 698

Miller R., Blanch L., Lenaghan S., Anderson A., Doe S., Bourke SJ.
Travelling abroad with cystic fibrosis: Assessment of risks and healthcare requirements
Respiratory Medicine 2017; 125: 92 - 93

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
European Journal of Health Economics 2017; 18: 73 - 82

Oddelisson DA., Sawicki GS.
Adherence and Recursive Perception among Young Adults with Cystic Fibrosis
Anthropology & Medicine 2017; 24: 65 - 80

Pisaturo M., Deppen A., Rochat I., Robinson WM., Hafen GM.
Death after cessation of treatment by cystic fibrosis patients: An international survey of clinicians
Palliative Medicine 2017; 31: 82 - 88

Vandeuleur M., Walte LM., Armstrong DS., Robinson P., Nixon GM., Horne RSC.
How Well do Children with Cystic Fibrosis Sleep? An Actigraphic and Questionnaire-Based Study

Vardar-Yaghi N., Saglam M., Inal-Ince D., Calik-Kutukcu E., Arikan H., Savci S., Ozelik U., Kiper N.
Hospitalization of Children with Cystic Fibrosis Adversely Affects Mothers’ Physical Activity, Sleep Quality, and Psychological Status
Journal of Child and Family Studies 2017; 26: 800 - 809

While AE., Heery E., Sheehan AM., Coyne I.
Health-related quality of life of young people with long-term illnesses before and after transfer from child to adult healthcare
Child Care Health and Development 2017; 43: 144 - 151
Davies G., Aurora P.
The use of multiple breath washout for assessing cystic fibrosis in infants

De Boeck K., Zolin A.
Year to year change in FEV1 in patients with cystic fibrosis and different-mutation classes
*Journal of Cystic Fibrosis* 2017; 16: 239 - 245

Donnola SB., Dassenbrook EC., Weaver D., Lu L., Gupta K., Prabhakaran A., Yu X., Chmiel JF., McMennat K., Konstan MW., Drumml ML., Flak CA.
Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients
*Journal of Cystic Fibrosis* 2017; 16: 283 - 290

Eickmeier O., Fussbroich D., Mueller K., Serve F., Smaczny C., Zielen S., Schubert R.
Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis

Engberink EO., Stanojevic S., Ratjen F.
Clinimetric Properties of the Lung Clearance Index in Adults and Children with Cystic Fibrosis
*Chest* 2016; 150: 1412 - 1413

Fayon M., Ladipo Y., Galode F., Debelleix S., Reix P.
Early lung disease in cystic fibrosis
*Archives de Pediatrie* 2016; 23:

Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis
*European Respiratory Journal* 2017; 49: 4:1601873

Kang SH., Meotti CD., Bombardelli K., Piltcher OB., Dalcin PDR.
Sinonasal characteristics and quality of life by SNOT-22 in adult patients with cystic fibrosis
*European Archives of Oto-Rhino-Laryngology* 2017; 274: 1873 - 1882

Liew Z., Mallikarjuna S., Hasan A., Gould FK., Bunn S., Thomas MF., Lordan JL., O’Brien C., Brodlie M.
Successful outcome following pharyngeotomy in a teenage boy with cystic fibrosis: a case report
*BMC Pulmonary Medicine* 2017; 17: ArNo: 17

Maglione M., Montella S., Mollica C., Carnovale V., Iacutucci P., De Gregorio F., Tosca A., Cervasio M., Raia V., Santamaria F.
Lung structure and function similarities between primary ciliary dyskinesia and mild cystic fibrosis: a pilot study
*Italian Journal of Pediatrics* 2017; 43: ArNo: 34

O’Neill K., Elborn JS., Tunney MM., Bradley JM.
Chinimetric Properties of the Lung Clearance Index in Adults and Children With Cystic Fibrosis Response
*Chest* 2016; 150: 1413 - 1414

O’Neill K., Tunney MM., Johnston E., Rowan S., Downey DG., Rendall J., Reid A., Bradbury I., Elborn JS., Bradley JM.
Lung Clearance Index in Adults and Children With Cystic Fibrosis
*Chest* 2016; 150: 1323 - 1332

Palser SC., Rayner OC., Leighton PA., Smyth AR.
Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study
*BMJ Open* 2016; 6: 12:e012303

Poncin W., Singer F., Aubriot AS., Lebecque P.
Agreement between multiple-breath nitrogen washout systems in children and adults
*Journal of Cystic Fibrosis* 2017; 16: 258 - 266

Ramsay KA., Sandhu H., Geake JB., Ballard E., O’Rourke P., Wainwright CE., Reid DW., Kidd TJ., Bell SC.
The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis
*Journal of Cystic Fibrosis* 2017; 16: 70 - 77

Rubin JL., Thayer S., Watkins A., Wagener JS., Hodkgins PS., Schechter MS.
Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States
*Current Medical Research and Opinion* 2017; 33: 667 - 674

Salamone L., Mondello B., Lucanto MC., Cristadoro S., Lombardo M., Barone M.
Bronchial tree-shaped mucous plug in cystic fibrosis: imaging-guided management
*Respirology Case Reports* 2017; 5: 2:UNSP e00214

Saunders C., Bayfield K., Irving S., Short C., Bush A., Davies JC.
Developments in multiple breath washout testing in children with cystic fibrosis
*Current Medical Research and Opinion* 2017; 33: 613 - 620

Saygi EK., Coskun OK.
Pulmonary rehabilitation in patients with cystic fibrosis
*Turkiye Fiziksel Tip Ve Rehabilitasyon Dergisi-turkish Journal of* 2017; 63: 96 - 103

Shaw L., Kinsey JE., Richards R., Shaw BS.
Individualized supervised resistance training during nebulization in adults with cystic fibrosis
*Pakistan Journal of Medical Sciences* 2016; 32: 1152 - 1157

Stahl M., Welput MO., Graeber SY., Joachim C., Sommerburg O., Kauczor HU., Puderbach M., Eichinger M., Mall MA.
Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis

Stanojevic S., Davis SD., Retsch-Bogart G., Webster H., Davis M., Johnson RC., Jensen R., Pizarro ME., Kane M., Clem CC., Schornick L., Subbarao P., Ratjen FA.
Progression of Lung Disease in Preschool Patients with Cystic Fibrosis
*American Journal of Respiratory and Critical Care Medicine* 2017; 195: 1216 - 1224

Thomen RP., Walkup LL., Roach DJ., Cleveland ZL., Clancy JP., Woods JC.
Hyperpolarized Xe-129 for investigation of mild cystic fibrosis lung disease in pediatric patients
*Journal of Cystic Fibrosis* 2017; 16: 275 - 282

White H., Shaw N., Denman S., Pollard K., Wynne S., Peckham DG.
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
*European Respiratory Journal* 2017; 49: 3:1600987

Radiology

DeBoer EM., Spielberg DR., Brody AS.
Clinical potential for imaging in patients with asthma and other lung disorders
*Journal of Allergy and Clinical Immunology* 2017; 139: 21 - 28

Kongstad T., Green K., Buchvald F., Skov M., Pressler T., Nielsen KG.
Association between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosis
*European Clinical Respiratory Journal* 2017; 4: ArNo: 1318027
Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
Journal of Cystic Fibrosis 2017; 16: 124 - 131

Transplantation
Beaume M., Kohler T., Greub G., Manuel O., Aubert JD., Baerlocher L., Farinelli L., Buckling A., van Delden C.
Rapid adaptation drives invasion of airway donor microbiota by Pseudomonas after lung transplantation
Scientific Reports 2017; 7: ArtNo: 40309

Cancer risk among lung transplant recipients with cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 91 - 97

Gilljam M., Nystrom U., Dellgren G., Skog I., Hansson L.
Survival after lung transplantation for cystic fibrosis in Sweden
European Journal of Cardio-thoracic Surgery 2017; 51: 571 - 576

Hayes D., Sweet SC., Benden C., Kopp BT., Goldfarb SB., Visner GA., Mallory GB., Tobias JD., Tumin D.
Transplant center volume and outcomes in lung transplantation for cystic fibrosis
Transplant International 2017; 30: 371 - 377

Liu Y., Vela M., Rudakevych T., Wigfield C., Garrity E., Saunders MR.
Patient factors associated with lung transplant referral and waitlist for patients with cystic fibrosis and pulmonary fibrosis
Journal of Heart and Lung Transplantation 2017; 36: 264 - 271

Urology
The transition of young adults with lifelong urological needs from pediatric to adult services: An international children's continence society position statement
Neurourology and Urodynamics 2017; 36: 811 - 819

Downes KJ., Dong M., Fukuda T., Clancy JP., Haffner C., Bennett MR., Vinks AA., Goldstein SL.
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis